WO2018037120A1 - Promédicaments activés par des espèces réactives de l'oxygène destinés à être utilisés dans le traitement de maladies inflammatoires et du cancer - Google Patents
Promédicaments activés par des espèces réactives de l'oxygène destinés à être utilisés dans le traitement de maladies inflammatoires et du cancer Download PDFInfo
- Publication number
- WO2018037120A1 WO2018037120A1 PCT/EP2017/071457 EP2017071457W WO2018037120A1 WO 2018037120 A1 WO2018037120 A1 WO 2018037120A1 EP 2017071457 W EP2017071457 W EP 2017071457W WO 2018037120 A1 WO2018037120 A1 WO 2018037120A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- amino
- compound
- group
- phenyl
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title claims abstract description 38
- 229940002612 prodrug Drugs 0.000 title claims abstract description 38
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 16
- 201000011510 cancer Diseases 0.000 title claims abstract description 16
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 14
- 238000011282 treatment Methods 0.000 title claims description 16
- 239000003642 reactive oxygen metabolite Substances 0.000 title abstract description 13
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims abstract description 75
- 229960000485 methotrexate Drugs 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 27
- 150000001875 compounds Chemical class 0.000 claims description 168
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 142
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 92
- -1 cyano, hydroxyl Chemical group 0.000 claims description 90
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 79
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 67
- 239000001257 hydrogen Substances 0.000 claims description 54
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 45
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 32
- 229960003896 aminopterin Drugs 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 27
- 229910052796 boron Inorganic materials 0.000 claims description 23
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 238000010511 deprotection reaction Methods 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 14
- 150000002431 hydrogen Chemical group 0.000 claims description 13
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims description 7
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 7
- 229940126142 compound 16 Drugs 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 6
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims description 6
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 6
- 125000001821 azanediyl group Chemical group [H]N(*)* 0.000 claims description 6
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims description 6
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims description 6
- 229940125833 compound 23 Drugs 0.000 claims description 6
- 201000001981 dermatomyositis Diseases 0.000 claims description 6
- VBXDEEVJTYBRJJ-UHFFFAOYSA-N diboronic acid Chemical compound OBOBO VBXDEEVJTYBRJJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 6
- 206010025135 lupus erythematosus Diseases 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 201000005962 mycosis fungoides Diseases 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 201000000306 sarcoidosis Diseases 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 206010009887 colitis Diseases 0.000 claims description 5
- 201000010901 lateral sclerosis Diseases 0.000 claims description 5
- 208000005264 motor neuron disease Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims description 4
- JEYHJOOCNIIPKV-FQEVSTJZSA-N (2S)-5-[(4-boronophenyl)methoxy]-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]-5-oxopentanoic acid Chemical compound B(O)(O)C1=CC=C(COC(CC[C@@H](C(=O)O)NC(C2=CC=C(C=C2)N(C)CC=2N=C3C(=NC(=NC3=NC=2)N)N)=O)=O)C=C1 JEYHJOOCNIIPKV-FQEVSTJZSA-N 0.000 claims description 4
- GLKALBAIXMBBOK-FQEVSTJZSA-N (4S)-5-[(4-boronophenyl)methoxy]-4-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]-5-oxopentanoic acid Chemical compound B(O)(O)C1=CC=C(COC([C@H](CCC(=O)O)NC(C2=CC=C(C=C2)N(C)CC=2N=C3C(=NC(=NC3=NC=2)N)N)=O)=O)C=C1 GLKALBAIXMBBOK-FQEVSTJZSA-N 0.000 claims description 4
- SUELFIMODWHPHE-UHFFFAOYSA-N 2-[[4-[(4-boronophenyl)methyl-[(2,4-diaminopteridin-6-yl)methyl]amino]benzoyl]amino]-5-oxo-5-(2-oxo-1,3-thiazolidin-3-yl)pentanoic acid Chemical compound B(O)(O)C1=CC=C(CN(C2=CC=C(C(=O)NC(C(=O)O)CCC(N3C(SCC3)=O)=O)C=C2)CC=2N=C3C(=NC(=NC3=NC=2)N)N)C=C1 SUELFIMODWHPHE-UHFFFAOYSA-N 0.000 claims description 4
- XWSGEVNYFYKXCP-UHFFFAOYSA-N 2-[carboxymethyl(methyl)amino]acetic acid Chemical compound OC(=O)CN(C)CC(O)=O XWSGEVNYFYKXCP-UHFFFAOYSA-N 0.000 claims description 4
- ULBRYNCEHUDRHD-UHFFFAOYSA-N 4-[[4-[(4-boronophenyl)methyl-[(2,4-diaminopteridin-6-yl)methyl]amino]benzoyl]amino]-5-oxo-5-(2-oxo-1,3-thiazolidin-3-yl)pentanoic acid Chemical compound B(O)(O)C1=CC=C(CN(C2=CC=C(C(=O)NC(CCC(=O)O)C(N3C(SCC3)=O)=O)C=C2)CC=2N=C3C(=NC(=NC3=NC=2)N)N)C=C1 ULBRYNCEHUDRHD-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- SXFVUUOYZUILGH-MHZLTWQESA-N [4-[[(2S)-5-[(4-boronophenyl)methoxy]-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]-5-oxopentanoyl]oxymethyl]phenyl]boronic acid Chemical compound B(O)(O)C1=CC=C(COC(CC[C@@H](C(=O)OCC2=CC=C(C=C2)B(O)O)NC(C2=CC=C(C=C2)N(C)CC=2N=C3C(=NC(=NC3=NC=2)N)N)=O)=O)C=C1 SXFVUUOYZUILGH-MHZLTWQESA-N 0.000 claims description 4
- 125000005336 allyloxy group Chemical group 0.000 claims description 4
- 229940125773 compound 10 Drugs 0.000 claims description 4
- 229940126543 compound 14 Drugs 0.000 claims description 4
- 229940125758 compound 15 Drugs 0.000 claims description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 4
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 claims description 3
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 claims description 3
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 claims description 3
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 claims description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims description 3
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 claims description 3
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 claims description 3
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 claims description 3
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 claims description 3
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 229940126639 Compound 33 Drugs 0.000 claims description 3
- 229940127007 Compound 39 Drugs 0.000 claims description 3
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000035561 Leukaemic infiltration brain Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 claims description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 claims description 3
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 claims description 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 3
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 3
- 229940126208 compound 22 Drugs 0.000 claims description 3
- 229940125807 compound 37 Drugs 0.000 claims description 3
- 229940127573 compound 38 Drugs 0.000 claims description 3
- 229940126540 compound 41 Drugs 0.000 claims description 3
- 229940125936 compound 42 Drugs 0.000 claims description 3
- 229940125844 compound 46 Drugs 0.000 claims description 3
- 229940127271 compound 49 Drugs 0.000 claims description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000030758 lung non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000025036 lymphosarcoma Diseases 0.000 claims description 3
- CRVGTESFCCXCTH-UHFFFAOYSA-N methyl diethanolamine Chemical compound OCCN(C)CCO CRVGTESFCCXCTH-UHFFFAOYSA-N 0.000 claims description 3
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 125000004257 pteridin-2-yl group Chemical group [H]C1=C([H])N=C2C([H])=NC(*)=NC2=N1 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 claims description 2
- UQKKZNUKMABTFA-UHFFFAOYSA-N 2-[[4-[[2-amino-4-[(4-boronophenyl)methoxycarbonylamino]pteridin-6-yl]methyl-methylamino]benzoyl]amino]-5-oxo-5-(2-oxo-1,3-thiazolidin-3-yl)pentanoic acid Chemical compound NC1=NC2=NC=C(N=C2C(=N1)NC(=O)OCC1=CC=C(C=C1)B(O)O)CN(C1=CC=C(C(=O)NC(C(=O)O)CCC(N2C(SCC2)=O)=O)C=C1)C UQKKZNUKMABTFA-UHFFFAOYSA-N 0.000 claims description 2
- YHUOTMGKFYOHAZ-UHFFFAOYSA-N 4-[[4-[[2-amino-4-[(4-boronophenyl)methoxycarbonylamino]pteridin-6-yl]methyl-methylamino]benzoyl]amino]-5-oxo-5-(2-oxo-1,3-thiazolidin-3-yl)pentanoic acid Chemical compound NC1=NC2=NC=C(N=C2C(=N1)NC(=O)OCC1=CC=C(C=C1)B(O)O)CN(C1=CC=C(C(=O)NC(CCC(=O)O)C(N2C(SCC2)=O)=O)C=C1)C YHUOTMGKFYOHAZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000005621 boronate group Chemical group 0.000 claims description 2
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 description 74
- 239000007787 solid Substances 0.000 description 60
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 51
- 239000000243 solution Substances 0.000 description 50
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 35
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 33
- 238000005481 NMR spectroscopy Methods 0.000 description 33
- 239000012299 nitrogen atmosphere Substances 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 29
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 28
- 238000002953 preparative HPLC Methods 0.000 description 26
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 21
- 239000003480 eluent Substances 0.000 description 19
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- 229940049906 glutamate Drugs 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 229960001866 silicon dioxide Drugs 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 238000003570 cell viability assay Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 229960002989 glutamic acid Drugs 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 229930195712 glutamate Natural products 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- SLYRGJDSFOCAAI-UHFFFAOYSA-N 1,3-thiazolidin-2-one Chemical compound O=C1NCCS1 SLYRGJDSFOCAAI-UHFFFAOYSA-N 0.000 description 6
- LWCXZSDKANNOAR-UHFFFAOYSA-N 4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(O)=O)C=C1 LWCXZSDKANNOAR-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 208000009386 Experimental Arthritis Diseases 0.000 description 6
- PDNOURKEZJZJNZ-UHFFFAOYSA-N [4-(bromomethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(CBr)C=C1 PDNOURKEZJZJNZ-UHFFFAOYSA-N 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- XRKLFEVNZWRMCT-UHFFFAOYSA-N 4-(phenylmethoxycarbonylamino)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC(=O)OCC1=CC=CC=C1 XRKLFEVNZWRMCT-UHFFFAOYSA-N 0.000 description 5
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 5
- KMQIBGKVZDBGAH-UHFFFAOYSA-N 6-(bromomethyl)pteridine-2,4-diamine;hydrobromide Chemical compound Br.N1=C(CBr)C=NC2=NC(N)=NC(N)=C21 KMQIBGKVZDBGAH-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- YRZQHWHYGDTYOP-UHFFFAOYSA-N benzyl n-(4-carbonochloridoylphenyl)carbamate Chemical compound C1=CC(C(=O)Cl)=CC=C1NC(=O)OCC1=CC=CC=C1 YRZQHWHYGDTYOP-UHFFFAOYSA-N 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000012417 linear regression Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- YFTHTJAPODJVSL-UHFFFAOYSA-N 2-(1-benzothiophen-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(SC=C2)C2=C1 YFTHTJAPODJVSL-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 4
- 239000007822 coupling agent Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- DJRQNWWJEOPZKC-UHFFFAOYSA-N 4-[methyl(phenylmethoxycarbonyl)amino]benzoic acid Chemical compound C=1C=C(C(O)=O)C=CC=1N(C)C(=O)OCC1=CC=CC=C1 DJRQNWWJEOPZKC-UHFFFAOYSA-N 0.000 description 3
- 0 CCC(*)C1C(C)(CN=O)CC1 Chemical compound CCC(*)C1C(C)(CN=O)CC1 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- MFUPLHQOVIUESQ-JEDNCBNOSA-N [(2s)-1,5-dimethoxy-1,5-dioxopentan-2-yl]azanium;chloride Chemical compound Cl.COC(=O)CC[C@H](N)C(=O)OC MFUPLHQOVIUESQ-JEDNCBNOSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- PVFNICPZVGDRRN-UHFFFAOYSA-N benzyl n-(4-carbonochloridoylphenyl)-n-methylcarbamate Chemical compound C=1C=C(C(Cl)=O)C=CC=1N(C)C(=O)OCC1=CC=CC=C1 PVFNICPZVGDRRN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- NTUGPDFKMVHCCJ-VIFPVBQESA-N ditert-butyl (2s)-2-aminopentanedioate Chemical compound CC(C)(C)OC(=O)CC[C@H](N)C(=O)OC(C)(C)C NTUGPDFKMVHCCJ-VIFPVBQESA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 125000005956 isoquinolyl group Chemical group 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- VXWBQOJISHAKKM-UHFFFAOYSA-N (4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C=C1 VXWBQOJISHAKKM-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000715 Mucilage Polymers 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N N,N′-Dicyclohexylcarbodiimide Substances C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ZVIDMSBTYRSMAR-UHFFFAOYSA-N N-Methyl-4-aminobenzoate Chemical compound CNC1=CC=C(C(O)=O)C=C1 ZVIDMSBTYRSMAR-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- CYNARAWTVHQHDI-UHFFFAOYSA-N (2,4-diaminopteridin-6-yl)methanol Chemical compound N1=C(CO)C=NC2=NC(N)=NC(N)=C21 CYNARAWTVHQHDI-UHFFFAOYSA-N 0.000 description 1
- XZHMPUJCSYVIQL-UHFFFAOYSA-N (2,4-diaminopteridin-6-yl)methanol;hydrochloride Chemical compound Cl.N1=C(CO)C=NC2=NC(N)=NC(N)=C21 XZHMPUJCSYVIQL-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MISZALMBODQYFT-URVXVIKDSA-N 125-69-9 Chemical compound Br.C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 MISZALMBODQYFT-URVXVIKDSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- RLVFZJURDMXLSL-NSHDSACASA-N CC(C)COC(CC[C@@H](C(OCC(C)C)=O)N)=O Chemical compound CC(C)COC(CC[C@@H](C(OCC(C)C)=O)N)=O RLVFZJURDMXLSL-NSHDSACASA-N 0.000 description 1
- NSPKXZJZBIJXSB-UHFFFAOYSA-N CC1(C)OB(c2ccc(CN=C=O)cc2)OC1(C)C Chemical compound CC1(C)OB(c2ccc(CN=C=O)cc2)OC1(C)C NSPKXZJZBIJXSB-UHFFFAOYSA-N 0.000 description 1
- UAEZCPJLURZHQA-LJAQVGFWSA-N CN(Cc1nc2c(N)nc(N)nc2nc1)c(cc1)ccc1C(N[C@@H](CCC(OCc(cc1)ccc1OC)=O)C(OCc(cc1)ccc1OC)=O)=O Chemical compound CN(Cc1nc2c(N)nc(N)nc2nc1)c(cc1)ccc1C(N[C@@H](CCC(OCc(cc1)ccc1OC)=O)C(OCc(cc1)ccc1OC)=O)=O UAEZCPJLURZHQA-LJAQVGFWSA-N 0.000 description 1
- YEJSPQZHMWGIGP-YFKPBYRVSA-N COC(CC[C@@H](C(OC)=O)N)=O Chemical compound COC(CC[C@@H](C(OC)=O)N)=O YEJSPQZHMWGIGP-YFKPBYRVSA-N 0.000 description 1
- 101100365877 Caenorhabditis elegans cdl-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 206010023774 Large cell lung cancer Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- YPJXLOUZOVHAIZ-UHFFFAOYSA-N [2-fluoro-4-(hydroxymethyl)phenyl]boronic acid Chemical compound OCC1=CC=C(B(O)O)C(F)=C1 YPJXLOUZOVHAIZ-UHFFFAOYSA-N 0.000 description 1
- IYJFMZDMFLQDCO-UHFFFAOYSA-N [4-(hydroxymethyl)-2-methylphenyl]boronic acid Chemical compound CC1=CC(CO)=CC=C1B(O)O IYJFMZDMFLQDCO-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- OCXGTPDKNBIOTF-UHFFFAOYSA-N dibromo(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(Br)(C=1C=CC=CC=1)(Br)C1=CC=CC=C1 OCXGTPDKNBIOTF-UHFFFAOYSA-N 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- KTNFJPQFZZYFPU-NSHDSACASA-N dimethyl (2s)-2-[(4-aminobenzoyl)amino]pentanedioate Chemical compound COC(=O)CC[C@@H](C(=O)OC)NC(=O)C1=CC=C(N)C=C1 KTNFJPQFZZYFPU-NSHDSACASA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 238000002732 pharmacokinetic assay Methods 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 238000003525 physicochemical assay Methods 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Definitions
- the present invention relates to prodrugs which are activated predominantly or exclusively in inflammatory tissue. More particularly, the present invention relates to prodrugs of methotrexate and derivatives thereof, which are selectively activated by Reactive Oxygen Species (ROS) in inflammatory tissues associated with cancer and inflammatory diseases such as rheumatoid arthritis (RA), juvenile dermatomyositis, psoriasis, psoriatic arthritis, lupus, sarcoidosis, Crohn's disease, colitis ulcerosa, multiple sclerosis, Amyotropic Lateral Sclerosis (ALS), atopic dermatitis, eczema etc.
- ROS Reactive Oxygen Species
- RA rheumatoid arthritis
- Prodrugs are masked forms of pharmacologically active agents designed to undergo in vivo activation by specific stimuli.
- prodrug chemical moieties that makes the drug in question inactive in healthy tissue and selectively activated in diseased tissue the side-effect profile and the selectivity may be improved significantly.
- ROS Reactive Oxygen Species
- Methotrexate is a well-known anti-cancer drug, a so-called anti-folate acting by inhibiting the metabolism of folic acid via dihydrofolate reductase. Methotrexate is also widely used as a disease- modifying treatment for some autoimmune diseases, including rheumatoid arthritis, juvenile dermatomyositis, psoriasis, psoriatic arthritis, lupus, sarcoidosis, and Crohn's disease. US 2015/0005352 Al discloses ROS-sensitive prodrug compositions and methods of treating ROS- associated diseases by administering the ROS-sensitive prodrug compositions.
- WO 2012/123076 Al relates to ferrocene-based compounds and their use as ROS-regulating prodrugs.
- Therapeutic Delivery 2012, 3, 823-833 discloses the use of boronic acids/esters as triggers for developing ROS-activated anticancer prodrugs that target cancer cells.
- ACHILLI, C. ET AL. "Folic acid-conjugated 4-Amino-Phenylboronate, a Boron-Containing Compound Designed for Boron Neutron Capture Therapy, is an Unexpected Agonist for Human Neutrophils and Platelets", CHEM BIO DRUG DES, vol. 83, 2013, p. 532-540 discloses folic acid-conjugated 4-amino- phenylboronate as a possible compound for the selective delivery of 10 B in Boron Neutron Capture Therapy (BNCT).
- BNCT Boron Neutron Capture Therapy
- ROSOWSKY A ET AL. "SYNTHESIS OF BIOLOGICAL ACTIVITY OF METHOTREXATE ANALOGUES WITH TWO ACID GROUPS AND A HYDROPHOBIC AROMATIC RING IN THE SIDE CHAIN", JOURNAL OF MEDICINAL CHEMISTRY AMERICAN CHEMICAL SOCIETY, US, vol. 34, no. 2, 1 January 1991, p. 574-579 discloses Y-(m-carboxyanilide) and Y-(m-boronoanilide) deivatives of methotrexate and ⁇ - (m-carboxyanilide) derivatives of aminopterin.
- US 2013/045949 Al discloses compounds that may be selectively activated to produce active anci- cancer agents in tumor cells.
- US 2014/0378673 Al relates to hypoxia selective prodrugs.
- prodrugs of ROS-sensitive drug compositions in particular prodrugs of methotrexate, which may be used for site-specific treatment, are stable and lend themselves for up-scaling.
- prodrugs of ROS-sensitive drug compositions in particular prodrugs of methotrexate, which are selectively activated in inflammatory tissues, have a beneficial cytotoxicity in target cells, low (no) cytotoxicity in healthy cells, are stable, and have a satisfactory bioavailability at the intended site of action.
- methotrexate of formula I are ROS-sensitive and are selectively activated in inflammatory tissues and thus lend themselves for site-specific treatment with methotrexate.
- the present invention relates to a compound of the formula I
- Rl and R2 are independently selected from the group consisting of hydrogen and a moiety of the formula II, III, IV, VII, VIII, IX, X, XI, or XII
- R3 is selected from the group consisting of hydrogen, Ci -6 alkyl, C 2 - 6 alkenyl, C 2 - 4 alkynyl, C 5 -i 2 aryl, C 4 . 11 heteroaryl and a moiety of the formula II, III, IV, VII, VIII, IX, X, XI, or XII above;
- R4 and R5 are independently selected from the group consisting of OH, 0-Ci- 6 alkyl, 0-C 2 - 6 alkenyl, 0-C 5 -i 2 aryl, 0-C 4 -uheteroaryl and a moiety of the formula V, VI, XIII, XIV, XV, XVI, or XVII;
- R6, R7 and R12 are independently selected from the group consisting of hydrogen, CF 3 , C 2 - 6 alkenyl, C 5 -i 2 aryl, and C 4 -uheteroaryl ;
- R8 and R9 are independently hydroxyl groups or R8 and R9 form, together with the intervening B and O atoms, a pinacol, catechol, diethanolamine, N-methyldiethanolamine or N- methyliminodiacetic acid (MIDA) boronate group;
- MIDA N-methyliminodiacetic acid
- W and Q are independently C or N; wherein each of X, Y and Z are selected from the group consisting of halogen, amino, nitro, cyano, hydroxyl, CF 3 , Ci -6 alkyl, Ci- 6 alkoxy, C 2 - 6 alkenyl, C 2 - 6 alkenyloxy, C 6 -i 2 aryl, C 4 -uheteroaryl ; wherein each of said Ci- 6 alkyl, C 2 - 6 alkenyl, C 6 -i 2 aryl, C 4 -uheteroaryl may be substituted by one or more substituents selected from the group consisting of halogen, amino, nitro, cyano, hydroxyl, CF 3 , and Ci- 6 alkyl; and each of a, b and c are integers in the range 0-4;
- X' and Y' are independently S or O, and R', R", R'" and R"" are independently selected from hydrogen, Ci- 5 alkyl, C 2 - 6 alkenyl, C 5 -i 2 aryl, C 4 -uheteroaryl, and Ci- 5 alkyl-C 5 -i 2 aryl ; wherein, if each of Rl, R2 and R3 are different from a moiety selected from a moiety of the formula II, III, IV, VII, VIII, IX, X, XI, or XII then at least one of R4 and R5 is a moiety of the formula V, XIII, XIV, XV, XVI, or XVII; as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof.
- the present invention relates to a method for the preparation of a compound according to the invention, comprising the steps: a) Providing methotrexate (MTX) of the formula 12 or aminopterin (AMT) of the formula 31
- RIO and Rl l is a leaving group LG; and c) Reacting optionally protected MTX (12) or optionally protected aminopterin (31) with a compound of formula Ila, Ilia, IVa, Vila, Villa, IXa, Xa, XIa, Xlla, XVIIIa, XlXa, XXa, XXIa, XXIIa, or XXIIIa to obtain a compound of formula I according to the invention;
- step c) or d) optionally reacting the compound obtained in step c) or d), as appropriate, with a compound of the formula Ila, Ilia, IVa, Via, Vila, Villa, IXa, Xa, XIa, Xlla, XVIIIa, XlXa, XXa, XXIa, XXIIa, or XXIIIa, followed by an optional deprotection step to obtain a compound of formula I according to the invention.
- a compound of the formula Ila, Ilia, IVa, Via, Vila, Villa, IXa, Xa, XIa, Xlla, XVIIIa, XlXa, XXa, XXIa, XXIIa, or XXIIIa followed by an optional deprotection step to obtain a compound of formula I according to the invention.
- a peptide coupling agent e.g . BOP, PyBOP, DCC, EDC, HATU, HOBt, etc. followed by addition of a compound of the formula XVIIIa, XlXa, or XXa, and a final deprotection step when needed, to obtain a compound of the formula I.
- Suitable coupling agents are known to a person skilled in the art and are disclosed in e.g . Chem. Rev. , 2011, 111 (11), 6557-6602.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound according to the invention, optionally in combination with one or more excipients.
- the present invention relates to a compound according to the invention as a prodrug for the treatment of inflammatory diseases or cancer.
- FIGURE 2 shows MCF-7 in vitro cell viability assay incubated with compounds 12 (methotrexate) and prodrug 16
- FIGURE 3 shows in vitro cell viability study of MCF-7 cells incubated for 48 h with 0.25, 0.062 and 0.015 ⁇ concentrations of compounds 12 (methotrexate) and 16;
- FIGURE 4 shows NCI-H460 in vitro cell viability assay incubated with compounds 12 (methotrexate) and prodrug 16
- FIGURE 6 shows activation of prodrugs under oxidative conditions (H 2 0 2 );
- FIGURE 7 shows NCI-H460 in vitro cell viability assay incubated with compounds 31 (aminopterin) and prodrug 23;
- FIGURE 8 shows MCF-7 in vitro cell viability assay incubated with compounds 31 (aminopterin) and prodrug 23;
- alkyl means a linear, cyclic or branched hydrocarbon group having 1 to 24 carbon atoms, such as methyl, ethyl, propyl, /so-propyl, cyclopropyl, butyl, /so-butyl, tert-butyl, cyclobutyl, pentyl, cyclopentyl, hexyl, and cyclohexyl .
- alkenyl means a linear, cyclic or branched hydrocarbon groups having 2 to 24 carbon atoms, and comprising (at least) one unsaturated bond .
- alkenyl groups are vinyl, allyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl and decaenyl .
- Preferred examples of alkenyl are vinyl, allyl, butenyl, especially allyl .
- alkynyl means a linear, cyclic or branched hydrocarbon groups having 2 to 24 carbon atoms, and comprising (at least) one triple bond. Examples of alkynyl groups are acetylene, propynyl, butynyl, pentynyl, and hexynyl.
- halogen includes fluoro, chloro, bromo, and iodo.
- alkoxy refers to a group -OR, wherein R is alkyl as defined above.
- alkenyloxy refers to a group -OR, wherein R is alkenyl as defined above.
- aryl refers to an unsaturated cyclic system.
- Aryl groups may comprise from 4-12 atoms, suitably from 6-8 atoms, most suitably 6 atoms.
- “Aryl” is preferably phenyl (-C 5 H 5 ).
- aromatic is intended to mean a carbocyclic ring system, such as phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracyl, phenanthracyl, pyrenyl, benzopyrenyl, fluorenyl and xanthenyl.
- heteroaryl groups are oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, coumaryl, furanyl, thienyl, quinolyl, benzothiazolyl, benzotriazolyl, benzodiazolyl, benzooxozolyl, phthalazinyl, phthalanyl, triazolyl, tetrazolyl, isoquinolyl, acridinyl, carbazolyl, dibenzazepinyl, indolyl, benzopyrazolyl, phenoxazonyl.
- heteroaryl groups are benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, furyl, thienyl, quinolyl, triazolyl, tetrazolyl, isoquinolyl, indolyl in particular benzimidazolyl, pyrrolyl, imidazolyl, pyridinyl, pyrimidinyl, furyl, thienyl, quinolyl, tetrazolyl, and isoquinolyl.
- pharmaceutically acceptable salt is intended to indicate salts prepared by reacting a compound of formula I with a suitable inorganic or organic acid, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, nitric, phosphoric, formic, acetic, 2,2-dichloroacetic, choline, adipic, ascorbic, L- aspartic, L-glutamic, galactaric, lactic, maleic, L-malic, phthalic, citric, propionic, benzoic, glutaric, gluconic, D-glucuronic, methanesulfonic, salicylic, succinic, malonic, tartaric, benzenesulfonic, ethane-l,2-disulfonic, 2-hydroxy ethanesulfonic acid, toluenesulfonic, sulfamic or fumaric acid .
- a suitable inorganic or organic acid such as hydrochloric, hydrobromic, hydroiodic,
- Pharmaceutically acceptable salts of compounds of formula I may also be prepared by reaction with a suitable base such as sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, ammonia, or suitable non-toxic amines, such as lower alkylamines, for example triethylamine, hydroxy-lower alkylamines, for example 2-hydroxyethylamine, bis-(2-hydroxyethyl)- amine, cycloalkylamines, for example dicyclohexylamine, or benzylamines, for example ⁇ , ⁇ ' - dibenzylethylenediamine, and dibenzylamine, or L-arginine or L-lysine.
- a suitable base such as sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, ammonia, or suitable non-toxic amines, such as lower alkylamines, for example triethylamine, hydroxy-lower alkylamines, for example 2-hydroxyethyl
- solvate is intended to indicate a species formed by interaction between a compound, e.g . a compound of formula I, and a solvent, e.g. alcohol, glycerol or water, wherein said species is in a solid form .
- a solvent e.g. alcohol, glycerol or water
- water is the solvent
- said species is referred to as a hydrate.
- the compounds of the formula I according to the invention may be prepared by the following steps: a) Providing methotrexate (MTX) of the formula 12 or aminopterin (AMT) of the formula 31 or any protected version of them. ;
- R4, R5, R6, R7, R8, R9, R12, R', R", R'", R"", W, Q, X, X', Y, Y' Z, a, b, c are as defined above,
- RIO and Rll is a leaving group LG; and c) Reacting optionally protected MTX ( 12) or optionally protected aminopterin (31) with a compound of formula Ila, Ilia, IVa, Vila, Villa, IXa, Xa, XIa, Xlla, XVIIIa, XlXa, XXa, XXIa, XXIIa, or XXIIIa to obtain a compound of formula I according to the invention ;
- step c) or d) optionally reacting the compound obtained in step c) or d), as appropriate, with a compound of the formula Ila, Ilia, IVa, Via, Vila, Villa, IXa, Xa, XIa, Xlla, XVIIIa, XlXa, XXa, XXIa, XXIIa, or XXIIIa, followed by an optional deprotection step to obtain a compound of formula I according to the invention .
- a compound of the formula Ila, Ilia, IVa, Via, Vila, Villa, IXa, Xa, XIa, Xlla, XVIIIa, XlXa, XXa, XXIa, XXIIa, or XXIIIa followed by an optional deprotection step to obtain a compound of formula I according to the invention .
- Methotrexate (MTX) of the formula 12 or aminopterin of the formula 31 are prepared with protecting groups at the desired positions when necessary. Suitable protective groups are known to a person skilled in the art and are disclosed in e.g . Wuts, P. G . M . & Greene, T. W. Greene's Protective Groups in Organic Synthesis. (Wiley, 2006) .
- Step b A non-limiting example of the process step a can be found in Preparation Example 8, 9 and 21 below. Step b
- a compound of the formula Ila, Ilia, IVa, Via, Vila, Villa, IXa, Xa, XIa, Xlla, XVIIIa, XlXa, XXa, XXIa, XXIIa, or XXIIIa may be provided commercially or may be prepared by a method known per se from commercially available starting compounds.
- Non-limiting examples of possible leaving groups include CI, Br, I, CDI, p-nitrophenol, etc..
- a compound of the formula Ila, Ilia or IVa may be prepared from the corresponding alcohol, transforming it into reactive species such a chloroformate or halide.
- Non-limiting examples are shown in Preparation Examples 1, 2 and 3, wherein the synthesis of compounds 1 , 3 and 5 is illustrated .
- a compound of the formula XXIa may be prepared from the corresponding amine, transforming it into the reactive isocyanate.
- Non-limiting examples are shown in Preparation Example 22, wherein the synthesis of compound 34 is illustrated .
- Step c Optionally protected methotrexate (MTX) of the formula 12 or aminopterin of the formula 31 is reacted with one or more compounds of the formula Ila, Ilia, IVa, Vila, Villa, IXa, Xa, XIa, Xlla, XVIIIa, XlXa, XXa, XXIa, XXIIa, XXIIIa in a manner known per se.
- Illustrative, non-limiting examples of said reaction can be found in Examples 1, 2, 3, 4, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 below.
- Step e The compound obtained in step c) or d), as appropriate, may optionally be reacted with a compound of the formula Ila, Ilia, IVa, Via, Vila, Villa, IXa, Xa, XIa, Xlla, XVIIIa, XlXa, XXa, XXIa, XXIIa, or XXIIIa, followed by an optional deprotection step, to obtain a compound of formula I according to the invention.
- Illustrative, non-limiting examples of said reaction can be found in Examples 19, 20, 21, 22, 23, 24 below.
- a peptide coupling agent e.g . BOP, PyBOP, DCC, EDC, HATU, HOBt, etc. followed by addition of a compound of the formula XVIIIa, XlXa, or XXa, and a final deprotection step when needed, to obtain a compound of the formula I.
- Suitable coupling agents are known to a person skilled in the art and are disclosed in e.g . Chem. Rev. , 2011, 111 (11), 6557-6602.
- An embodiment of the invention is a compound of the formula I, wherein Rl and R2 are independently selected from the group consisting of hydrogen and a moiety of the formula II, III, or IV.
- An embodiment of the invention is a compound of the formula I, wherein R3 is selected from the group consisting of hydrogen, Ci_ 5 alkyl, C 2 - 5 alkenyl, C 2 . 4 alkynyl, C 5 _i 2 aryl, C 4 .nheteroaryl and a moiety of the formula II, III, or IV.
- An embodiment of the invention is a compound of the formula I, wherein R4 and R5 are independently selected from the group consisting of OH, 0-Ci- 6 alkyl, 0-C 2 - 6 alkenyl, 0-C 6 -i 2 aryl, O- C 4 -uheteroaryl and a moiety of the formula V, or VI
- An embodiment of the invention is a compound of the formula I, wherein Rl and R2 are independently selected from the group consisting of hydrogen and a moiety of the formula II, III, or IV;
- R3 is selected from the group consisting of hydrogen, Ci- 6 alkyl, C 2 - 6 alkenyl, C 2 . 4 alkynyl, C 6 -i 2 aryl, C 4 . 11 heteroaryl and a moiety of the formula II, III, or IV;
- R4 and R5 are independently selected from the group consisting of OH, 0-Ci- 6 alkyl, 0-C 2 - 6 alkenyl, 0-C 6 -i 2 aryl, 0-C 4 -uheteroaryl and a moiety of the formula V, or VI; and wherein, if each of Rl, R2 and R3 are different from a moiety selected from a moiety of the formula II, III, and IV, then at least one of R4 and R5 is a moiety of the formula V.
- An embodiment of the invention is a compound of the formula I, wherein W and Q are both C.
- Another embodiment of the invention is a compound of the formula I, wherein W is C and Q is N.
- Another embodiment of the invention is a compound of the formula I, wherein W is N and Q is C.
- Another embodiment of the invention is a compound of the formula I, wherein W and Q are both N.
- An embodiment of the invention is a compound of formula I, wherein R6 and R7 are independently selected from the group consisting of hydrogen and Ci- 6 alkyl, preferably selected from the group consisting of hydrogen and Ci- 4 alkyl, preferably selected from the group consisting of hydrogen and methyl, preferably wherein R6 and R7 are both hydrogen.
- An embodiment of the invention is a compound of formula I, wherein R8 and R9 are independently hydroxyl groups or R8 and R9 form, together with the intervening B and O atoms, a pinacol or catechol group, preferably wherein R8 and R9 are independently hydroxyl groups or R8 and R9 form, together with the intervening B and O atoms, a pinacol group, preferably wherein R8 and R9 are both hydroxyl groups.
- An embodiment of the invention is a compound of formula I, wherein each of X, Y and Z are selected from the group consisting of halogen, cyano, hydroxyl, CF 3 , and Ci- 6 alkyl ; and each of a, b and c are 0, 1 or 2.
- An embodiment of the invention is a compound of formula I, wherein each of X, Y and Z are selected from the group consisting of halogen, cyano, hydroxyl, and Ci- 6 alkyl ; and each of a, b and c are 0 or 1.
- An embodiment of the invention is a compound of formula I, wherein each of X, Y and Z are selected from the group consisting of halogen and Ci- 4 alkyl; and each of a, b and c are 0 or 1.
- An embodiment of the invention is a compound of formula I, wherein each of X, Y and Z are selected from the group consisting of fluoro and methyl; and each of a, b and c are 0 or 1.
- An embodiment of the invention is a compound of the formula I, wherein R2 is selected from the group consisting of
- Rl is hydrogen
- R3 is selected from the group consisting of hydrogen and Ci_ 5 alkyl, preferably selected from the group consisting of hydrogen and Ci- 4 alkyl, preferably wherein said R3 is methyl;
- R4 and R5 are selected from the group consisting of OH and 0-Ci- 5 alkyl, preferably selected from the group consisting of OH and 0-Ci- 4 alkyl, preferably wherein R4 and R5 are both methoxy or hydroxy.
- An embodiment of the invention is a compound of the formula I, wherein R3 is selected from the group consisting of
- Rl and R2 are hydrogen
- R4 and R5 are selected from the group consisting of OH and 0-Ci_ 5 alkyl, preferably selected from the group consisting of OH and 0-Ci- 4 alkyl, preferably wherein R4 and R5 are both methoxy or hydroxy.
- An embodiment of the invention is a compound of the formula I, wherein R4 and/or R5 is a moiety of the formula
- Rl and R2 are hydrogen
- R3 is selected from the group consisting of hydrogen and Ci- 6 alkyl, preferably selected from the group consisting of hydrogen and Ci- 4 alkyl, preferably wherein said R3 is methyl .
- An embodiment of the invention is a compound of the formula I, wherein Y' is S.
- An embodiment of the invention is a compound of the formula I, wherein X' is O.
- An embodiment of the invention is a compound of the formula I, wherein R' and R" are both hydrogen .
- Compounds of formula I may comprise asymmetrically substituted (chiral) carbon atoms and carbon-carbon double bonds which may give rise to the existence of stereoisomeric forms, e.g . enantiomers, diastereomers and geometric isomers.
- the present invention includes all such isomers, either in pure form or as mixtures thereof.
- the compounds of formula I may be obtained in crystalline form either directly by concentration from an organic solvent or by crystallisation or recrystallisation from an organic solvent or mixture of said solvent and a cosolvent that may be organic or inorganic, such as water.
- the crystals may be isolated in essentially solvent-free form or as a solvate, such as a hydrate.
- the invention covers all crystalline modifications and forms and also mixtures thereof.
- the present invention further relates to a pharmaceutical composition
- a pharmaceutical composition comprising as an active ingredient an effective amount of at least one compound of the Formula I, or pharmaceutically acceptable salt thereof and/or stereoisomer thereof, optionally in combination with one or more conventional excipients.
- the pharmaceutical composition of the present invention usually comprises 0.1-90wt% of the compound of Formula I and/or physiologically acceptable salt thereof.
- the pharmaceutical composition can be prepared according to methods known in the art. For this purpose, if necessary, the compound of Formula I and/or a stereoisomer thereof is combined with one or more solid or liquid pharmaceutically acceptable excipients and/or adjuvants, to form an application form or dosage form suitable for administration to a human.
- the compound of Formula I of the present invention or the pharmaceutical composition containing the same can be administered in unit dosage form, and the administration routes can be intestinal or parenteral administration, such as oral, intramuscular, subcutaneous, nasal, oral mucosal, skin, intraperitoneal or rectal administration.
- the administration dosage form can be, for example, tablets, capsules, drop pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, buccal tablets, suppositories, lyophilized powder injections, can be normal preparations, sustained-release preparations, controlled-release preparations, and various microparticle administration systems.
- various carriers well known in the art can be widely used.
- the examples of the carriers can be, for example, diluents and absorbents, such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, aluminum silicate; wetting agent and binding agent, such as water, glycerol, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia mucilage, gelatin mucilage, sodium carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone; disintegrants, such as, dry starch powder, alginate, agar powder, laminarin powder, sodium hydrogen carbonate and citric acid, calcium carbonate, polyoxyethylene sorbitol fatty acid ester, sodium dodecyl sulfate, methyl cellulose, ethyl cellulose; disintegr
- the tablets can be further processed into coated tablets, for example, sugar coated tablets, thin film coated tablets, enteric-coated tablets, or double-layer tablets or multi-layer tablets.
- various carriers known in the art can be used.
- the examples of the carriers can be, for example, diluents and absorbing agents, such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, kaolin, talc; binding agent, such as acacia gum, tragacanth gum, gelatin, ethanol, honey, liquid sugar, rice paste or panada; disintegrants, such as agar powder, dry starch powder, alginate, sodium dodecyl sulfonate, methyl cellulose, ethyl cellulose.
- various carriers known in the art can be widely used.
- the examples of the carriers can be, for example, polyethylene glycol, lecithin, cocoa butter, fatty alcohol, ester of fatty alcohol, gelatin, semi-synthetic ester.
- the compound of Formula I or stereoisomer thereof as effective component is mixed with the various carriers, and the resultant mixture is placed in hard gelatin capsule shells or soft capsules.
- the compound of Formula I or stereoisomer thereof as effective component can also be processed into microcapsules, suspended in aqueous medium to form a suspension, or placed in hard capsules or processed into injections.
- a preparation for injection such as solution, emulsion, lyophilized powder injection and suspension
- all diluents known in the art for example, water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, multi-oxidized isostearyl alcohol, polyoxyethylene sorbitol fatty acid ester, could be used.
- an isotonic injection solution an suitable amount of sodium chloride, glucose or glycerol can be added to the injection preparation, and conventional co-solvent, buffer agent, and pH regulator can further added.
- flavouring agents preservatives, flavoring agents, correctants, sweetening agents or other materials can also be added to the pharmaceutical compositions.
- the administration dose of the compound of Formula I, or a stereoisomer thereof may depend on many factors, for example, the properties and severity of the diseases to be prevented or treated, the gender, age, bodyweight and individual reaction of patient or animal, the specific compound to be used, the administration routes and times, and so on.
- the dose can be of single dose form or can be divided into several dose forms, such as, two, three or four dose forms.
- the compounds according to the invention may be used as a prodrug for the treatment of inflammatory diseases or cancer.
- inflammatory diseases include rheumatoid arthritis (RA), juvenile dermatomyositis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, lupus, sarcoidosis, atopic dermatitis, eczema, Crohn's disease, uveitis associated with juvenile idiopathic arthritis or ulcerative colitis, colitis ulcerosa, multiple sclerosis, Amyotropic Lateral Sclerosis (ALS), non-infectious ocular inflammation, vasculitis, systemic lupus erythematosus, and eosinophilic fasciitis.
- RA rheumatoid arthritis
- psoriasis juvenile rheumatoid arthritis
- psoriatic arthritis psoriatic arthritis
- lupus sarcoidosis
- Non-limiting examples of cancer diseases include acute lymphocytic leukemia, meningeal leukemia, myeloproliferative neoplasm, breast cancer, squamous cell carcinoma, lymphosarcoma, osteosarcoma, advanced mycosis fungoides (cutaneous T cell lymphoma), small cell types lung cancer, non-small cell lung cancer, and non-Hodgkin's lymphoma.
- Analytical TLC was conducted on Merck aluminium sheets covered with silica (C60) .
- the plates were either visualized under UV-light or stained by dipping in a developing agent followed by heating .
- KMn0 4 (3 g in water (300 mL) along with K 2 C0 3 (20 g) and 5% aqueous NaOH (5 mL)) or Ninhydrin (3 g in a mixture of n-butanol (200 mL) and AcOH (6 mL)) were used as developing agents.
- Flash column chromatography was performed using Matrex 60 A, 35-70 ⁇ silicagel.
- Method A eluents A (0.1% HC0 2 H in mili-Q water) and B (0.1% HC0 2 H in CH 3 CN) were used in a linear gradient (5% B to 100% B) in a total run time of 2.6 min.
- Method B eluents A (0.1% HC0 2 H in H 2 0) and B (0.1% HC0 2 H in CH 3 CN) were used in a linear gradient (5% B to 100% B) in a total run time of 5.0 min.
- Method C eluents A (lOmM NH 4 OAc in mili-Q water) and B (0.1% NH 4 OAc in mili-Q water /MeCN, 90/10, v/v) were used in a linear gradient (5% B to 100% B) in a total run time of 2.6 min.
- Method D eluents A (0.1% NH 4 OAc in H 2 0) and B (0.1% NH 4 OAc in CH 3 CN) were used in a linear gradient (5% B to 100% B) in a total run time of 5.0 min
- the LC system was coupled to a SQD mass spectrometer operating in both positive and negative electrospray modes. The temperature for all recordings was approximately 20 °C.
- Analytical LC- HRMS (ESI) analysis was performed on an Agilent 1100 RP-LC system equipped with a diode array detector using a Phenomenex Luna C18 column (d 3 ⁇ , 2.1 x 50 mm ; column temp: 40 °C; flow: 0.4 mL/min) .
- Eluents A (0.1% HC0 2 H in H 2 0) and B (0.1% HC0 2 H in CH 3 CN) were used in a linear gradient (20% B to 100% B) in a total run time of 15 min.
- the LC system was coupled to a Micromass LCT orthogonal time-of-flight mass spectrometer equipped with a Lock Mass probe operating in positive or negative electrospray mode.
- Elution was carried out in a reversed-phase gradient fashion combining Al (0.1% HC0 2 H in mili-Q water) and Bl (0.1% HC0 2 H in CH 3 CN) or A2 (5 m M N H 4 OAc in H 2 0) and B2 (5 m M N H 4 OAc in CH 3 CN) : 5% B to 70 % B in 10 min, hold for 3.5 min, then 70% B to 100% B in 1.5 min, and hold 3 minutes. Total run time : 20 min .
- 2,4-diamino-6-(hydroxymethyl)pteridine hydrochloride (4.40 g, 19.2 mmol) was dissolved in hot water (150 mL) and after cooling to 21 °C the solution was neutralized with 1M NaOH aq. solution to pH 7 (ca. 20 mL) . The formed precipitates were collected by filtration, washed with water, and dried in vacuo over P 2 0 5 to afford an orange-beige solid corresponding to 2,4-diamino-6- (hydroxymethyl)pteridine. The solid was suspended in dry DMAc (25 mL) and triphenylphosphine dibromide ( 18.1 g, 42.9 mmol) was added to the suspension.
- the reaction was allowed to warm to 21 °C and stirred for 5 h under a N 2 atmosphere.
- the mixture was diluted with CH 2 CI 2 (100 mL), washed with 1M HCI (2 x75 mL), sat. NaHC0 3 (2 x 75mL), and brine (75 mL) .
- the organic phase was dried over Na 2 S0 4 , filtered, and concentrated in vacuo to afford a yellow solid (770 mg) that was purified by preparative HPLC.
- the CH 3 CN/H 2 0 fractions containing the pinacolate intermediate were poured together into a 250mL round bottom flask and HCI cc. (0.3 mL, ca. pH 2) was added .
- reaction mixture was stirred for 16 h at 21 °C and quenched with sat. NaHC0 3 (ca. 50 mL) . After removal of the CH 3 CN in vacuo the formed precipitate was filtered, washed with H 2 0 and dried in vacuo to afford the title compound 9 (122 mg, 27%) as a yellow solid.
- the solid residue was purified by preparative HPLC.
- the CH 3 CN/H 2 0 fractions containing the pinacolate intermediate were poured together into a 250mL round bottom flask and HCI cc. (0.3 mL, ca. pH 2) was added.
- the reaction mixture was stirred for 16h at room temperature and quenched with sat. NaHC0 3 (ca. 50 mL) .
- After removal of the CH 3 CN in vacuo the formed precipitate was filtered, washed with H 2 0 and dried in vacuo to afford the title compound 10 (179 mg, 22%) as a yellow solid.
- the reaction was allowed to warm to 21 °C and stirred for 5 h under a N 2 atmosphere.
- the mixture was diluted with CH 2 CI 2 (100 mL), washed with 1M HCI (2 x75 mL), sat. NaHC0 3 (2 x 75mL) and brine (75 mL) .
- the organic phase was dried over Na 2 S0 4 , filtered and concentrated in vacuo.
- the solid residue was purified by preparative HPLC.
- the CH 3 CN/H 2 0 fractions containing the pinacolate intermediate were poured together into a 250mL round bottom flask and HCI cc. (0.3 mL, ca. pH 2) was added .
- methotrexate (12) 1.0 g, 2.20 mmol
- anhydrous DMF 50 mL
- 1, 1,3,3-tetramethylguanidine 0.55 mL, 4.4 mmol
- 4-methoxybenzyl chloride 0.59 mL, 4.4 mmol
- reaction mixture was stirred for 16h at 21 °C and quenched with sat. NaHC0 3 (ca. 50 mL) . After removal of CH 3 CN in vacuo, the precipitate was filtered, washed with H 2 0 and dried in vacuo to afford 30 as a yellow solid (131 mg, 39%) .
- the reaction was allowed to warm to 21 °C and stirred for 5 h under a N 2 atmosphere.
- the crude mixture was concentrated in vacuo to afford a dark yellow solid .
- the solid residue was purified by preparative HPLC.
- the CH 3 CN/H 2 0 fractions containing the pinacolate intermediate were poured together into a 250mL round bottom flask and HCI cc. (0.3 mL, ca. pH 2) was added .
- the reaction mixture was stirred for 16h at room temperature and quenched with excess of sat. NaHC0 3 (ca. 50 mL) .
- the reaction was allowed to warm to 21 °C and stirred for 16 h under a N 2 atmosphere.
- the mixture was diluted with CH 2 CI 2 (100 mL), washed with 1 M aq. HCI (2 x75 ml_), sat. aq. NaHC0 3 (2 x 75mL), and brine (75 mL).
- the organic phase was dried over Na 2 S0 4 , filtered, and concentrated in vacuo to afford a solid that was purified by preparative HPLC.
- the CH 3 CN/H 2 0 fractions containing the pinacolate intermediate were poured together and HCI cc. was added until pH ⁇ 2.
- the reaction mixture was stirred for 16 h at 21 °C and quenched with sat.
- Chemical Stability pH 7.4 / PBS stability Chemical stability at pH 7.4 for compounds 16 and 23 was assessed using diclofenac as an internal standard.
- To 490 ⁇ _ of a pre-warmed solution of 20 ⁇ diclofenac in PBS (0.1% DMSO) is added 10 ⁇ ⁇ . of a ImM DMSO solution of compound 16 and 23 (in triplicates) .
- the mixture was incubated at 1000 rpm at 37 °C in an Eppendorf Thermomixer C ( 1.5 mL) and samples were taken for analysis by RP-UPLC-MS after 30 min, lh, 2h, 4h, 8h, 24h and 48h.
- Solubility Kinetic solubility at 100 ⁇ with 1% DMSO. Briefly, the kinetic solubility, utilizing test compound from 10 mM DMSO stock solution, is measured at a final compound concentration of 100 ⁇ and 1% DMSO. Test compound is added to 100 mM potassium phosphate buffer, pH 7.4, and incubated at 37 °C for 20 hours in a heater-shaker. After incubation, the samples are centrifuged at 3000xg at 37 °C for 30 min to pellet insoluble material and an aliquot of the supernatant is taken for analysis. After dilution of the sample, the concentration of dissolved compound is quantified by LC-MS/MS analysis. Plasma protein binding assay.
- the fraction unbound drug (f u ) in plasma from human or other animal species was determined by equilibrium dialysis at 37 °C for 4 hours using a Rapid Equilibrium Dialysis (RED) device.
- the drug molecule at a concentration of 10 ⁇ is added to 50% plasma and dialyzed against isotonic phosphate buffer (67 mM, pH 7.4). After dialysis, the drug concentration in the buffer and plasma is quantified by LC-MS/MS analysis.
- the stability of the drug molecule in plasma is determined by incubating drug- spiked plasma (10 ⁇ ) at 37 °C for 4 hours, meanwhile the control plasma sample is kept in the freezer. The concentration of drug in both samples is quantified by LC-MS/MS analysis.
- the in vitro metabolic stability assay uses liver microsomes. Compound is dissolved in 100 mM KP0 4 buffer pH 7.4 to a ⁇ final concentration. The assay is initiated by addition of NADPH and incubated for up to 40 min (THERMOstar, BMG Lab Technologies) with microsomes. Experiments are terminated at different time points by addition of acetonitrile. The amount of parent compound remaining is analyzed by LC-MS/MS. The natural logarithm of relative amount parent compound remaining is plotted against time and the first-order rate constant of consumption is determined by linear regression. In vitro half life is expressed in minutes and in vitro clearance in ⁇ /img x min), respectively.
- the human breast cancer MCF-7 (Sigma) and human large cell lung cancer NCIH-460 (ATTC) cell lines were cultured in a humidified, 5% C0 2 atmosphere at 37 °C in Dulbecco ' s Modified Eagle ' s Medium (DMEM) (Sigma) or Roswell Park Memorial Institute medium (RPMI) 1640 (Sigma) supplemented with 10% fetal bovine serum (FBS, heat- inactivated, Fisher Scientific) and 1% penicillin/streptomycin. Both cell lines were subcultured every 2-3 days.
- DMEM Dulbecco ' s Modified Eagle ' s Medium
- RPMI 1640 Roswell Park Memorial Institute medium
- FBS fetal bovine serum
- Fisher Scientific heat- inactivated, Fisher Scientific
- MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-te-trazolium (MTS) assay (Promega Biotech AB, Sweden ) was used to determine the in vitro antiproliferative effect of the compounds. This assay is based on the principle that cells have the ability to reduce MTS tetrazolium, while, when dead, they lose this ability. MCF-7 and NCI-H460 cells were cultured in 96-well plates at an initial density of 10 4 cells/well (MCF-7) or 7xl0 3 cells/well (NCI-H460) in their respective growth medium.
- the medium was removed and the cells were incubated in the presence or absence of pre-activated compounds at different concentrations.
- the MTS reagent was added to each well .
- the cells were further incubated for a period of time between 30-60 min at 37 °C until colorimetric reaction was developed within the linear range and the absorbance of the samples was measured at 490 nm using a 96-well plate spectrophotometer (Victor 3 plate reader with Wallac 1420 Workstation vs 3.0 software).
- a control was used for each tested compound, where cells were incubated with DMEM or RPMI containing the equivalent concentration of DMSO (maximum of 0.4% v/v). Each concentration of tested compounds was done in triplicates. The final concentration of H202 in each well was always ⁇ 10 ⁇ (non-cytotoxic concentration in MCF-7 and NCI-H460 cell lines, determined with the described assay). The IC 50 values were calculated using GraphPad Prism v6.0 (California, USA) as the concentration of the compounds required to cause 50% response compared to cells exposed to controls using a non-linear dose-response regression.
- FIGURE 2 shows MCF-7 in vitro cell viability assay incubated with compounds 12 (methotrexate) and prodrug 16.
- Cells were incubated at increasing concentrations of tested compouns for 48 h before MTS reagent was added .
- Pre-activation of tested compounds with H 2 0 2 was performed 24 h before experiment started as described in the experimental section.
- FIGURE 4 shows NCI-H460 in vitro cell viability assay incubated with compounds 12 (methotrexate) and prodrug 16. Cells were incubated at increasing concentrations of tested compouns for 48 h before MTS reagent was added .
- Pre-activation of tested compounds with H 2 0 2 was performed 24 h before experiment started as described in the experimental section.
- FIGURE 6 shows activation of prodrugs under oxidative conditions (H 2 0 2 ) . The activation was run at a test compound concentration of 50 ⁇ and H 2 0 2 of 0.5 mM in a mixture of 30% DMSO in PBS. The experiment was run in triplicates. Values are represented as mean and error bars as SD. Error bars not shown are smaller than the symbol .
- FIGURE 7 shows NCI-H460 in vitro cell viability assay incubated with compounds 31 (aminopterin) and prodrug 23.
- Cells were incubated at increasing concentrations of tested compounds for 48 h before MTS reagent was added .
- Pre-activation of tested compounds with H 2 0 2 was performed 24 h before experiment started as described in the experimental section.
- FIGURE 8 shows MCF-7 in vitro cell viability assay incubated with compounds 31 (aminopterin) and prodrug 23.
- mice Male, 8-9 weeks were obtained from Janvier, France. The mice were maintained in the animal house at Redoxis, Medicon Village, Lund, Sweden, where they were acclimatized for approximately one week before initiation of the experiment. All animal experiments were approved by the local animal ethic committee Malmo/Lund, Sweden, approved under the license N165-15.
- CIA collagen induced arthritis
- CFA Complete Freund's Adjuvant
- Vehicle and compound 2% DMSO in PBS, Life Technologies, injection volume 370 ⁇
- mice with score exceeding 45 were removed from the experiment.
- the general health of mice was evaluated three times per week after disease induction. As an indicator of general health, animal body weight was used.
- DBA/IJ mice were given the indicated amounts of compound daily and disease progression vas evaluated three times per week starting on day 27.
- One animal in vehicle group and one animal in 23 group were sacrificed pre-termination due to high score.
- the AMT group was removed pre- termination due to a decline in health.
- Data represents mean values of arthritic score ⁇ SEM.
- * represents a p-value ⁇ 0.05 and ** represents a p-value ⁇ 0.01 for comparison between MTX and vehicle, while ⁇ represents a p-value ⁇ 0.05 for comparison between 16 and vehicle.
- Rl and R2 are selected from the group consisting of hydrogen and a moiety of the formula II, III or IV
- R3 is selected from the group consisting of hydrogen, Ci_ 5 alkyl, C 2 - 6 alkenyl, C 2 - 4 alkynyl, C 5 . i 2 aryl, C 4- n heteroaryl and a moiety of the formula II, III or IV above,
- R4 and R5 are independently selected from the group consisting of OH, 0-Ci- 6 alkyl, 0-C 2 . 5 alkenyl, 0-C 6 -i 2 aryl, 0-C 4 -uheteroaryl and a moiety of the formula V or VI;
- R6 and R7 are independently selected from the group consisting of hydrogen, CF 3 , Ci- 6 alkyl, C 2 - 6 alkenyl, C 6 -i 2 aryl, and C 4 -uheteroaryl;
- R8 and R9 are independently hydroxyl groups or R8 and R9 form, together with the intervening B and O atoms, a pinacol, catechol, diethanolamine, N-methyldiethanolamine or MIDA boronate group;
- W and Q are independently C or N; wherein each of X, Y and Z are selected from the group consisting of halogen, amino, nitro, cyano, hydroxyl, CF 3 , Ci- 6 alkyl, Ci- 6 alkoxy, C 2 - 6 alkenyl, C 2 - 6 alkenyloxy, C 6 -i 2 aryl, C 4 .
- Ci- 6 alkyl, C 2 - 6 alkenyl, C 6 -i 2 aryl, C 4 -uheteroaryl may be substituted by one or more substituents selected from the group consisting of halogen, amino, nitro, cyano, hydroxyl, CF 3 , and Ci_ 5 alkyl; and each of a, b and c are integers in the range 0-4;
- X' and Y' are independently S or O, and R' and R" are independently selected from hydrogen, Ci- 6 alkyl, C 2 - 6 alkenyl, aryl and Ci- 6 alkyl-aryl; wherein, if each of Rl, R2 and R3 are different from a moiety selected from a moiety of the formula II, III and IV, then at least one of R4 and R5 is a moiety of the formula V; as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof.
- ASPECT 4 The compound according to any one of the preceding aspects, wherein R8 and R9 are independently hydroxyl or R8 and R9 form, together with the intervening B and O atoms, a pinacol or catechol group, preferably wherein R8 and R9 are independently hydroxyl or R8 and R9 form, together with the intervening B and O atoms, a pinacol group, preferably wherein R8 and R9 are both hydroxyl groups.
- each of X, Y and Z are selected from the group consisting of halogen, cyano, hydroxyl, CF 3 , and Ci- 5 alkyl ; and each of a, b and c are 0, 1 or 2.
- R2 is selected from the group consisting of
- Rl is hydrogen
- R3 is selected from the group consisting of hydrogen and Ci- 6 alkyl, preferably selected from the group consisting of hydrogen and Ci- 4 alkyl, preferably wherein said R3 is methyl; and R4 and R5 are selected from the group consisting of OH and 0-Ci- 5 alkyl, preferably selected from the group consisting of OH and 0-Ci_ 4 alkyl, preferably wherein R4 and R5 are both methoxy or hydroxy.
- Rl and R2 are hydrogen
- R4 and R5 are selected from the group consisting of OH and 0-Ci- 5 alkyl, preferably selected from the group consisting of OH and 0-Ci- 4 alkyl, preferably wherein R4 and R5 are both methoxy or hydroxy.
- Rl and R2 are hydrogen
- R3 is selected from the group consisting of hydrogen and Ci- 6 alkyl, preferably selected from the group consisting of hydrogen and Ci- 4 alkyl, preferably wherein said R3 is methyl.
- a method for the preparation of a compound of the formula I comprising the steps: a) Providing methotrexate (MTX) of the formula 12 or aminopterin of the formula 31 or any protected versions of them
- R4, R5, R6, R7, R8, R9, R', R", W, Q, X, X', Y, Y' Z, a, b, c are as defined above,
- RIO and Rl l is a leaving group LG; and c) Reacting optionally protected MTX(12) or optionally protected aminopterin (31) with a compound of formula Ila, Ilia, IVa, or VI to obtain a compound of formula I according to the invention;
- a pharmaceutical composition comprising a compound according to any one of aspects 1-12 optionally in combination with one or more excipients.
- a compound according to any one of aspects 1-12 as a prodrug for the treatment of inflammatory diseases or cancer such as wherein said inflammatory disease is selected from the group consisting of rheumatoid arthritis (RA), juvenile dermatomyositis, psoriasis, psoriatic arthritis, lupus, sarcoidosis, atopic dermatitis, eczema Crohn's disease, colitis ulcerosa, multiple sclerosis, and Amyotropic Lateral Sclerosis (ALS).
- RA rheumatoid arthritis
- juvenile dermatomyositis juvenile dermatomyositis
- psoriasis psoriatic arthritis
- lupus lupus
- sarcoidosis atopic dermatitis
- eczema Crohn's disease colitis ulcerosa
- multiple sclerosis multiple sclerosis
- ALS Amyotropic Lateral Sclerosis
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des promédicaments activés principalement ou exclusivement dans des tissus inflammatoires, plus particulièrement des promédicaments de méthotrexate et leurs dérivés, qui sont activés sélectivement par des espèces réactives de l'oxygène (ROS) dans des tissus inflammatoires associés au cancer et à des maladies inflammatoires, ainsi qu'un procédé de préparation desdits promédicaments.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16185890.7 | 2016-08-26 | ||
EP16185890 | 2016-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018037120A1 true WO2018037120A1 (fr) | 2018-03-01 |
Family
ID=56842670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/071457 WO2018037120A1 (fr) | 2016-08-26 | 2017-08-25 | Promédicaments activés par des espèces réactives de l'oxygène destinés à être utilisés dans le traitement de maladies inflammatoires et du cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018037120A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109096319A (zh) * | 2018-10-09 | 2018-12-28 | 贺州学院 | 一种检测过氧化氢的新型近红外比率荧光探针及其制备方法和应用 |
CN110156823A (zh) * | 2019-06-14 | 2019-08-23 | 淮阴工学院 | 一种无毒甲氨蝶呤前药及其制备方法 |
US20200113906A1 (en) * | 2017-05-10 | 2020-04-16 | University Of Massachusetts | Crosslinked polymer nanoparticles for targeted cellular uptake and therapeutics, and compositions and methods thereof |
CN112321625A (zh) * | 2020-11-30 | 2021-02-05 | 河西学院 | 一种基于叶酸的mida硼酸酯-萘二甲酰亚胺类化合物及其制备与应用 |
CN113896657A (zh) * | 2021-11-16 | 2022-01-07 | 山东盛安贝新能源有限公司南京分公司 | 一种索马鲁肽保护氨基酸的合成方法及纯化方法 |
CN114249731A (zh) * | 2020-09-24 | 2022-03-29 | 南京海润医药有限公司 | 一种甲氨蝶呤中间体的精制方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012123076A1 (fr) | 2011-03-11 | 2012-09-20 | Ruprecht-Karls-Universität Heidelberg | Composés à base de ferrocène et leur utilisation comme promédicaments régulant les espèces réactives de l'oxygène (ros) |
US20130045949A1 (en) | 2011-07-01 | 2013-02-21 | Uwm Research Foundation, Inc. | Anti-cancer agents |
US20140378673A1 (en) | 2012-02-13 | 2014-12-25 | University Of Tsukuba | Prodrug using nitroimidazole |
US20150005352A1 (en) | 2013-06-26 | 2015-01-01 | The Regents Of The University Of California | Reactive oxygen species-based prodrugs |
-
2017
- 2017-08-25 WO PCT/EP2017/071457 patent/WO2018037120A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012123076A1 (fr) | 2011-03-11 | 2012-09-20 | Ruprecht-Karls-Universität Heidelberg | Composés à base de ferrocène et leur utilisation comme promédicaments régulant les espèces réactives de l'oxygène (ros) |
US20130045949A1 (en) | 2011-07-01 | 2013-02-21 | Uwm Research Foundation, Inc. | Anti-cancer agents |
US20140378673A1 (en) | 2012-02-13 | 2014-12-25 | University Of Tsukuba | Prodrug using nitroimidazole |
US20150005352A1 (en) | 2013-06-26 | 2015-01-01 | The Regents Of The University Of California | Reactive oxygen species-based prodrugs |
Non-Patent Citations (11)
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200113906A1 (en) * | 2017-05-10 | 2020-04-16 | University Of Massachusetts | Crosslinked polymer nanoparticles for targeted cellular uptake and therapeutics, and compositions and methods thereof |
CN109096319A (zh) * | 2018-10-09 | 2018-12-28 | 贺州学院 | 一种检测过氧化氢的新型近红外比率荧光探针及其制备方法和应用 |
CN110156823A (zh) * | 2019-06-14 | 2019-08-23 | 淮阴工学院 | 一种无毒甲氨蝶呤前药及其制备方法 |
CN114249731A (zh) * | 2020-09-24 | 2022-03-29 | 南京海润医药有限公司 | 一种甲氨蝶呤中间体的精制方法 |
CN114249731B (zh) * | 2020-09-24 | 2023-09-29 | 南京海润医药有限公司 | 一种甲氨蝶呤中间体的精制方法 |
CN112321625A (zh) * | 2020-11-30 | 2021-02-05 | 河西学院 | 一种基于叶酸的mida硼酸酯-萘二甲酰亚胺类化合物及其制备与应用 |
CN113896657A (zh) * | 2021-11-16 | 2022-01-07 | 山东盛安贝新能源有限公司南京分公司 | 一种索马鲁肽保护氨基酸的合成方法及纯化方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018037120A1 (fr) | Promédicaments activés par des espèces réactives de l'oxygène destinés à être utilisés dans le traitement de maladies inflammatoires et du cancer | |
EP3039020B1 (fr) | Inhibiteurs d'ido | |
US8865756B2 (en) | Inhibitors of HCV NS5A | |
EP3917526A1 (fr) | Composés et leurs utilisations | |
IL213277A (en) | A5ns inhibitors of jaundice virus c | |
JP6616411B2 (ja) | 新規な、nik阻害剤としてのピラゾール誘導体 | |
KR102659213B1 (ko) | Jak1 선택적 억제제 | |
CA3042731A1 (fr) | Inhibiteurs de kinases associees au recepteur de l'interleukine -1 et leurs utilisations | |
EP2575475A1 (fr) | Inhibiteurs de ns5a de vhc | |
EP3917517A1 (fr) | Composés et leurs utilisations | |
EP3686199B9 (fr) | Dérivé à cycle fusionné utilisé en tant qu'inhibiteur du récepteur a2a | |
CN115484952A (zh) | 被取代的吡啶酮-吡啶基化合物的方法、组合物和结晶形式 | |
CN110759908A (zh) | 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 | |
CN107987072B (zh) | 作为crth2抑制剂的吲哚类化合物 | |
EP3560928B1 (fr) | Composé imidazole fusionné ayant une activité inhibitrice de l'indoléamine 2,3-dioxygénase | |
CN106414468A (zh) | 富马酸‑co‑释放分子杂合物、其在治疗炎性或心血管疾病中的用途和其制备方法 | |
CN106232602B (zh) | 氘代喹唑啉酮化合物以及包含该化合物的药物组合物 | |
EP3475285B1 (fr) | Cible mécaniste d'inhibiteurs de la voie de signalisation de la rapamycine et ses applications thérapeutiques | |
EP4053108A1 (fr) | Composé contenant un noyau benzénique et son application | |
CN108264500B (zh) | 取代的2-氨基吡啶类化合物及制备方法 | |
WO2021175317A1 (fr) | Cristal de composé tricyclique agissant sur la protéine crbn et son procédé de préparation | |
WO2019233366A1 (fr) | Antagoniste sélectif du récepteur a2a | |
KR20220110744A (ko) | 암 줄기 세포를 표적화하는 암 치료 | |
RU2428414C2 (ru) | Способ получения амидов креатина | |
WO2018037119A1 (fr) | Promédicaments activés par des espèces réactives de l'oxygène destinés à être utilisés dans le traitement de maladies inflammatoires et du cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17761225 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17761225 Country of ref document: EP Kind code of ref document: A1 |